Pfizer sues Novo, Metsera
Digest more
Metsera-Pfizer-Novo updates; Why the FDA drug chief resigned; The “big flaw” in Big Pharma’s patient advocacy.
CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.
Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...
Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...
For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...
Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...
In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life ...
There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, a move aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback